Advanced Search
REVIEW ARTICLE
Korean J Pediatr 2011 March;54(3) :106-110.
doi:https://doi.org/10.3345/kjp.2011.54.3.106
Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
Hong Hoe Koo (Koo HH)
Department of Pediatrics, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul,Korea
Corresponding Author: Hong Hoe Koo ,Tel: +82.2-3410-3539, Fax: +82.2-3410-0043, Email: hhkoo@skku.edy
Copyright © 2011 by The Korean Pediatric Society
ABSTRACT
In pediatric patients with acute lymphoblastic leukemia (ALL), the Philadelphia chromosome translocation is uncommon, with a frequency of less than 5%. However, it is classified as a high or very high risk, and only 20‒30% of Philadelphia chromosome-positive (Ph+) children with ALL are cured with chemotherapy alone. Allogeneic hematopoietic stem cell transplantation from a closely matched donor cures 60% of patients in first complete remission. Recent data suggest that chemotherapy plus tyrosine kinase inhibitors (TKIs) may be the initial treatment of choice for Ph+ ALL in children. However, longer observation is required to determine whether long-term outcome with intensive imatinib and chemotherapy is indeed equivalent to that with allogeneic related or alternative donor hematopoietic stem cell transplantation (HSCT). Reports on the use of second-generation TKIs in children with Ph+ ALL are limited. A few case reports have indicated the feasibility and clinical benefit of using dasatinib as salvage therapy enabling HSCT. However, more extensive data from clinical trials are needed to determine whether the administration of secondgeneration TKIs in children is comparable to that in adults. Because Ph+ ALL is rare in children, the question of whether HSCT could be a dispensable part of their therapy may not be answered for some time. An international multicenter study is needed to answer the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in children with Ph+ ALL.
Keywords: Philadelphia chromosome | Acute lymphoblastic leukemia | Tyrosine kinase inhibitor | Child
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
  via Pubmed
Full text via PMC  Full text via PMC
via Pubreader  via PubReader
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
1,063
View
7
Download
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia  2017 May;60(5)
Acute lymphoblastic leukemia in children: past, present and future  2007 July;50(7)
Platelet count change by vincristine in maintenance phase of acute lymphoblastic leukemia chemotherapy  2006 February;49(2)
A Case of Congenital Acute Megakaryoblastic Leukemia with Down Syndrome  1997 April;40(4)
Acute Megakaryoblastic Leukemia in Children  1993 January;36(1)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.